Sputnik Light / Gamaleya Research Institute 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal, Adverse events:  COVID-19 Vaccines Breakthrough Infections and Adverse Effects Reported by the Birzeit University Community in Palestine. (Pubmed Central) -  Aug 5, 2024   
    This study aimed to explore the type and severity of short-term adverse reactions associated with BNT162 (Pfizer-BioNTech), mRNA 1273 (Moderna), and viral vector vaccines and to compare the incidence of post-vaccination Covid-19 infection among the Birzeit University community in Palestine...The study included participants aged 18 years and older who were vaccinated with Pfizer, Moderna, Sputnik Light, or Sputnik v. A total of 558 participants who were administered COVID-19 vaccine were included in the study...Furthermore, the Pfizer/BioNTech COVID-19 vaccine group reported fewer commonly reported side effects (fever, chills, headache, fatigue, muscle pain, joint pain, nausea, and dizziness), followed by the Moderna and viral vector vaccines. Females and underweight participants experienced more adverse effects with both vaccines, and fewer common side effects were reported by all participants.
  • ||||||||||  Journal:  Comparative Analysis of SARS-CoV-2 Antibody Responses across Global and Lesser-Studied Vaccines. (Pubmed Central) -  Mar 28, 2024   
    The vaccines under comparison include well-known ones like Pfizer (BNT162b2) and AstraZeneca (ChAdOx1-S), alongside less-studied vaccines including Soberana (Soberana 02), Abdala (CIGB-66), and Sputnik V/Sputnik Light...Overall, we found no evidence of waning in the antibody magnitude across vaccines. Our study supports the conclusion that populations with high infection rates still benefit substantially from vaccination.
  • ||||||||||  Sputnik Light / Gamaleya Research Institute
    Disparities in Anti-SARS-CoV-2 Reactivity According to Vaccines in the Era of Omicron in Cameroon (Poster hall) -  Mar 5, 2024 - Abstract #CROI2024CROI_158;    
    Regarding COVID-19 vaccination, 67.5%(1652/2449) had received at least one dose (48.7% Pfizer, 24.8% Johnson&Johnson, 18.2% Moderna; 8.1% AstraZeneca, 4.8% Sinopharm and 0.2% Sputnik-light); among these, 55.0%(909/1652) were fully vaccinated and 37.1%(613/1652) received additional boost doses...The high-rate of COVID-19 antibodies suggests herd immunity at community-level in Cameroon, during the wide circulation of Omicron. Furthermore, vaccination with Pfizer appears with higher Covid-19 antibody response, supporting the need for vaccine update with novel variants, especially with the rapid antibody weaning (~5months) in this tropical setting.
  • ||||||||||  Sputnik Light / Gamaleya Research Institute
    Observational data, Journal, Adverse events:  Assessing the prevalence and patterns of COVID-19 vaccine side effects among Syrian adults: A cross-sectional study. (Pubmed Central) -  Jan 29, 2024   
    This study aimed to assess the prevalence and patterns of COVID-19 vaccine side effects among Syrian adults, with a focus on the AstraZeneca and Sputnik Light vaccines, in light of the low vaccination rate in Syria (below 18%) attributed to fear of side effects...Our study found that COVID-19 vaccines are well tolerated among the Syrian population, with short-term side effects that typically resolve within three days. These findings are expected to bolster vaccination rates through enhanced public confidence and acceptance.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  Comparison of the Immunogenicity of five COVID-19 vaccines in Sri Lanka. (Pubmed Central) -  Sep 30, 2022   
    The Moderna vaccine elicited the highest ACE2 blocking antibody levels followed by Sputnik V/AZD1222, while those who received Sinopharm had the lowest levels. These findings highlight the need for further studies to understand the effects on clinical outcomes.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance. (Pubmed Central) -  Jun 25, 2022   
    The effectiveness in cases of more severe forms was higher than for less severe ones. Thus, present study indicates the high protective efficacy of vaccination against hospitalization with COVID-19 in case of Omicron lineage.
  • ||||||||||  SAFETY OF VACCINES AGAINST COVID-19 IN PATIENTS WITH SPONDYLOARTHRITIS (PRELIMINARY DATA). () -  May 24, 2022 - Abstract #EULAR2022EULAR_4062;    
    According to preliminary data, the tolerability of vaccines against COVID-19 in patients with SpA is satisfactory. Further studies with an increased sample are needed to study the safety, immunogenicity and clinical efficacy of immunization against COVID-19 in patients of this cohort.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    SAFETY OF COVID-19 VACCINES IN PATIENTS WITH RHEUMATOID ARTHRITIS (PRELIMINARY DATA). () -  May 24, 2022 - Abstract #EULAR2022EULAR_4026;    
    According to preliminary data, the tolerance of vaccines against COVID-19 in RA patients is satisfactory. Further studies are needed to study the safety, immunogenicity and clinical efficacy of immunization against COVID-19 in patients of this cohort.
  • ||||||||||  Sputnik Light / Gamaleya Research Institute
    Journal:  Boosting of the SARS-CoV-2-Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine. (Pubmed Central) -  Mar 8, 2022   
    Additionally, we found a strong correlation between RBD-specific IgG titers and VNA in serum, and according to these data vaccination may be recommended when the RBD-specific IgG titers drop to 142.7 binding Ab units/ml or below. In summary, the results of the study demonstrate that vaccination is beneficial for both COVID-19-naive and recovered individuals, especially since it raises serum VNA against the B.1.617.2 variant, one of the five SARS-CoV-2 variants of concern.
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford
    Review, Journal:  Review of COVID-19 viral vector-based vaccines and COVID-19 variants. (Pubmed Central) -  Feb 12, 2022   
    The technology has been used to make Ebola vaccines and now COVID-19 vaccines...Current adenovirus vector-based vaccines being administered against SARS-CoV-2 infection are JNJ-78435735 by Johnson and Johnson (Janssen) along with Beth Israel Deaconess Medical Center, AZD1222 by Oxford-AstraZeneca, Sputnik V and Sputnik Light by Gamaleya Research Institute of Epidemiology and Microbiology, and Convidecia vaccine by CanSino Biologics...Efficacy against COVID-19 variants has been found in all but the Convidecia vaccine so far. Heterologous prime-boost COVID-19 vaccination regimen may be the new face and more efficient immunization approach for enhanced immunity against COVID-19.
  • ||||||||||  Sputnik Light / Gamaleya Research Institute
    Enrollment open:  Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light (clinicaltrials.gov) -  Feb 21, 2021   
    P3,  N=6000, Recruiting, 
    Russian Direct Investment Fund. Not yet recruiting --> Recruiting